CAR-T cell therapy targeting surface expression of TYRP1 to treat cutaneous and rare melanoma subtypes

Area of Science:

• Oncology
• Immunotherapy
• Cellular Therapy

Background:

• Developing chimeric antigen receptor (CAR)-T cell therapies for solid tumors is challenging due to the need for tumor-specific surface targets.
• Identifying targets with high tumor expression and minimal normal tissue expression is crucial for efficacy and safety.
• Melanoma subtypes, particularly those resistant to immune checkpoint blockade, require novel therapeutic strategies.

Purpose of the Study:

• To identify a suitable surface protein target for CAR-T cell therapy in melanoma.
• To develop and evaluate a TYRP1-specific CAR-T cell therapy for melanoma treatment.
• To assess the efficacy and safety of TYRP1 CAR-T cell therapy in preclinical models.

Main Methods:

• Identification of Tyrosinase Related Protein 1 (TYRP1) as a potential CAR-T cell target.
• Development of a sensitive CAR-T cell therapy targeting surface TYRP1.
• In vitro and in vivo testing in murine and patient-derived melanoma models (cutaneous, acral, uveal).

Main Results:

• TYRP1 CAR-T cells demonstrated antitumor activity against TYRP1-overexpressing melanoma cells.
• Therapy showed efficacy in various preclinical melanoma models, including cutaneous, acral, and uveal subtypes.
• No significant systemic or off-tumor toxicities were observed in immunocompetent murine models.

Conclusions:

• TYRP1 is a viable and promising target for CAR-T cell therapy in melanoma.
• TYRP1 CAR-T cell therapy exhibits significant antitumor efficacy and a favorable safety profile.
• These findings support the progression of TYRP1 CAR-T cell therapy towards clinical trials.